Product Description
VX-210, formerly referred to as BA-210 or Cethrin, is a cell-permeable derivative of the bacterial enzyme, C3 transferase, that inhibits Rho activity through covalent modification and therefore has the potential to independently block Rho-mediated axonal growth cone collapse and inhibit neuronal apoptosis post-SCI.
Mechanisms of Action: ROCK Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioAxone BioSciences
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Spinal Cord Injuries
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VX15-210-101 | P3 |
Terminated |
Spinal Cord Injuries |
2018-11-01 |
|
| BA-210-201 | P3 |
Withdrawn |
Spinal Cord Injuries |
2016-05-01 |
|
| BA-210-101 | P2 |
Completed |
Spinal Cord Injuries |
2008-12-01 |
|
| ALSE-C-01 | P2 |
Withdrawn |
Spinal Cord Injuries |
None |